Novo Nordisk Oral Weight Loss Drug Gains Early Traction in the United States Following Launch
Novo Nordisk recorded 3,071 prescriptions in four days for its new weight-loss pill. This marks the first oral treatment to reach the American retail market.
Insights:
Novo Nordisk A/S officially launched its oral weight-loss medication Wegovy on January 5, 2026, marking a significant milestone as the first pill of its kind to enter the US 
USmarket. Early retail data from IQVIA indicated that 3,071 prescriptions were filled within the first four days of availability, a figure that excluded prescriptions processed through online pharmacies such as NovoCare Pharmacy. Following the release of this performance indicator, shares of the company rose by 5 percent as investors reacted to the initial uptake metrics.
USmarket. Early retail data from IQVIA indicated that 3,071 prescriptions were filled within the first four days of availability, a figure that excluded prescriptions processed through online pharmacies such as NovoCare Pharmacy. Following the release of this performance indicator, shares of the company rose by 5 percent as investors reacted to the initial uptake metrics.
